Compare MUJ & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUJ | EYPT |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.2M | 1.5B |
| IPO Year | 1998 | 2005 |
| Metric | MUJ | EYPT |
|---|---|---|
| Price | $12.00 | $12.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 84.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,031.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $3.91 |
| 52 Week High | $12.68 | $19.11 |
| Indicator | MUJ | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 30.29 | 36.53 |
| Support Level | $11.93 | $12.05 |
| Resistance Level | $12.17 | $13.32 |
| Average True Range (ATR) | 0.10 | 1.01 |
| MACD | -0.06 | -0.33 |
| Stochastic Oscillator | 6.25 | 3.45 |
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.